Current filters:


8251 to 8260 of 97217 results

Non-insulin antidiabetics market set to soar to $8 billion by 2020


Non-insulin dependent (type 2) diabetes accounts for 90% of all diagnosed cases of diabetes. The leading…

DiabetesMarkets & MarketingPharmaceutical

Value of new cancer medicines to patients evolve overtime, PhRMA report shows


Following Food and Drug Administration approval of a new cancer medicine, it often takes years of additional…

BiotechnologyNorth AmericaOncologyPharmaceuticalRegulationResearch

Pharming considers options, including a sale of the company


Netherland-based biotech company Pharming Group (NYSE Euronext: PHARM) yesterday revealed that it is…

BiotechnologyLicensingMergers & AcquisitionsPharmingRare diseasesResearchRuconest

$25 million milestone for Protalix following US approval of Elelyso


Israel-based Protalix BioTherapeutics (TASE:PLX) has received a $25 million milestone payment from global…

ElelysoFinancialPfizerPharmaceuticalProtalix BioTherapeuticsRare diseases

Lilly to increase equity position in China's Novast by $20 million


US pharma major Eli Lilly (NYSE: LLY) says it will increase of its network of manufacturing capabilities…

Asia-PacificEli LillyGenericsMergers & AcquisitionsNovast LaboratoriesPharmaceutical

More news from American Diabetes Association meeting


Ongoing news from the American Diabetes Association meeting in Philadelphia (see also The Pharma Letter…

Boehringer IngelheimDiabetesEli LillyLantusLY2605541PharmaceuticalResearchSanofi

Alkermes and J&J initiate Ph III trial of three-month Invega Sustenna


USA-based Alkermes (Nasdaq: ALKS) and partner health care giant Johnson & Johnson (NYSE: JNJ) have started…

AlkermesInvega SustennaJohnson & JohnsonNeurologicalPharmaceuticalResearch

8251 to 8260 of 97217 results

Back to top